Subtype
Female Reproductive System Neoplasm
CI-CAN-00000885Explore in graph →
Non-malignant1,630 active trials11 approved drugs139 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000885Explore in graph →
Clinical trials
7,171 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06644677 | Third-Generation Nanopore HPV Integration Site for Precise Prediction of Cervical Cancer Prognosis | completed | — | 200 | Peking Union Medical College HospitalOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06313268 | Safety of Effivia®, a Bevacizumab Biosimilar | completed | — | 83 | Laboratorios LiomontINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06629831 | Systemic Inflammatory Biomarkers in Ovarian Cancer | completed | — | 90 | Bakirkoy Dr. Sadi Konuk Research and Training HospitalOTHER_GOV | 1 | Oct 9, 2024 | clinicaltrials |
| NCT03635489 | A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 3 | 100 | Hoffmann-La RocheINDUSTRY | 1 | Oct 3, 2024 | clinicaltrials |
| NCT04927013 | Connecting Families to Overcome Ovarian Cancer | completed | N/A | 2,331 | Emory UniversityOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT02480374 | Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer | completed | Phase 1 | 18 | ImunonINDUSTRY | 1 | Oct 2, 2024 | clinicaltrials |
| NCT06623916 | Strain-elastography in Endometrial Cancer | completed | — | 63 | Alper seyhanOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT05359952 | Women's Health Communication Study | completed | N/A | 32 | Fox Chase Cancer CenterOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT03648489 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)(DICE) | completed | Phase 2 | 134 | Imperial College LondonOTHER | 2 | Sep 20, 2024 | clinicaltrials |
| NCT05775549 | A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer(FLAME) | completed | — | 24 | AstraZenecaINDUSTRY | 1 | Sep 20, 2024 | clinicaltrials |
| NCT02903771 | Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. | completed | Phase 1 | 32 | Kazia Therapeutics LimitedINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT05002868 | Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors | completed | Phase 1 | 23 | Rhizen Pharmaceuticals SAINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT05344950 | Connecting Audio and Radio Sensing Systems to Improve Care at Home(AURA) | completed | — | 13 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05518812 | Carboprost (Hemabate) for Fibroid Resection | completed | Early Phase 1 | 19 | Northwestern UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05700669 | Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 3 | Valerio TherapeuticsINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06297187 | Cavitronic Ultrasonic Surgical Aspiration (CUSA) Women's Health Study | completed | — | 56 | Integra LifeSciences CorporationINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06599749 | Establishment and Standardization of a Platform for In-depth Tumour Profiling (TUPRO) in Patients With Advanced and Metastatic High-Grade Adenocarcinoma of Ovarian, Tubal or Peritoneal Origin (TUPRO-Gyn) | completed | — | 80 | University Hospital, Basel, SwitzerlandOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03598270 | Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer(ANITA) | completed | Phase 3 | 417 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 5 | Aug 30, 2024 | clinicaltrials |
| NCT02431676 | Survivorship Promotion In Reducing IGF-1 Trial(SPIRIT) | completed | Phase 2 | 121 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT05783167 | Self-collected Vaginal and Urine Samples in HIV-positive Women | completed | — | 502 | University of AarhusOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT01696032 | SGI-110 in Combination With Carboplatin in Ovarian Cancer(SGI-110) | completed | Phase 2 | 120 | Astex Pharmaceuticals, Inc.INDUSTRY | 3 | Aug 27, 2024 | clinicaltrials |
| NCT05362955 | 5-fluorouracil Following Cervical Intraepithelial Neoplasia Treatment Among HIV-positive Women in East Africa | completed | Phase 1 | 12 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 23, 2024 | clinicaltrials |
| NCT01606241 | Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | 24 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT03402841 | Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients(OPINION) | completed | Phase 3 | 279 | AstraZenecaINDUSTRY | 19 | Aug 21, 2024 | clinicaltrials |
| NCT03766672 | Characterization of the Genetic Profile of Type 2 Endometrial Carcinoma in Martinique(ENDO-NGS-MQ) | completed | — | 30 | University Hospital Center of MartiniqueOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT01164735 | Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer | completed | — | 169 | Gynecologic Oncology GroupNETWORK | 1 | Aug 14, 2024 | clinicaltrials |
| NCT01198171 | Racial and Genetic Biomarkers of Response in Tissue Samples From Patients With Endometrial Cancer | completed | — | 243 | Gynecologic Oncology GroupNETWORK | 1 | Aug 14, 2024 | clinicaltrials |
| NCT01344837 | Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer | completed | — | 360 | Gynecologic Oncology GroupNETWORK | 1 | Aug 14, 2024 | clinicaltrials |
| NCT04067960 | Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer | completed | Early Phase 1 | 197 | Mayo ClinicOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT03539406 | Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients(INTRO) | completed | Phase 1 | 11 | Radboud University Medical CenterOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05132868 | Assessments of Genetic Counseling Augmented With an Educational Video or Pamphlet Versus Traditional Counseling | completed | N/A | 78 | Stanford UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05454865 | The Effect of Jin Si Herbal Tea on Cancer-related Fatigue of Gynecological Cancer Patients | completed | N/A | 21 | Buddhist Tzu Chi General HospitalOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT02009579 | ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix Cancer | completed | Phase 2 | 120 | Belgian Gynaecological Oncology GroupOTHER | 4 | Aug 7, 2024 | clinicaltrials |
| NCT03133286 | Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)(RADIANT) | completed | — | 16 | DxTerity DiagnosticsINDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT03206177 | Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary | completed | Phase 1 | 26 | University of OklahomaOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT04296890 | A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression(SORAYA) | completed | Phase 3 | 106 | ImmunoGen, Inc.INDUSTRY | 11 | Aug 7, 2024 | clinicaltrials |
| NCT06537687 | Relational Agents in Cervical Cancer Education (RACE)(RACE) | completed | N/A | 91 | Radhika GogoiOTHER | 1 | Aug 5, 2024 | clinicaltrials |
| NCT03154281 | Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast | completed | Phase 1 | 14 | Avera McKennan Hospital & University Health CenterOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06524934 | Virtual Reality's Role in See&Treat Hysteroscopy | completed | N/A | 116 | Federico II UniversityOTHER | 1 | Jul 29, 2024 | clinicaltrials |
| NCT02020707 | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers | completed | Phase 1 | 43 | Mayo ClinicOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT03602586 | Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 2 | Jul 26, 2024 | clinicaltrials |
| NCT03830866 | Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)(CALLA) | completed | Phase 3 | 770 | AstraZenecaINDUSTRY | 15 | Jul 26, 2024 | clinicaltrials |
| NCT02923934 | A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers | completed | Phase 2 | 120 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06517433 | First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b | completed | Phase 1 | 62 | Mersana TherapeuticsINDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06517485 | First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b | completed | Phase 1 | 142 | Mersana TherapeuticsINDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06518070 | Results Comparison of Cervical Cancer Early Detection Using Cerviray With VIA Test | completed | — | 44 | Universitas PadjadjaranOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT02501954 | Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol | completed | Phase 3 | 48 | Women's Cancer Care Associates, LLCOTHER | 2 | Jul 23, 2024 | clinicaltrials |
| NCT03218436 | Physical Cold Atmospheric Plasma for the Treatment of Cervical Intraepithelial Neoplasia(CAPCIN) | completed | N/A | 63 | University Hospital TuebingenOTHER | 1 | Jul 23, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Oct 16, 2024source: clinicaltrials